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Summary
Background: Azathioprine (AZA)-induced pancreatitis is an unpredictable and dose-

2

Division of Gastroenterology, Department
of Medicine, Western University, London,
ON, Canada
3

independent adverse event affecting 2%-7% of patients with inflammatory bowel
disease (IBD) patients treated with AZA. There are no tools in clinical practice to
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ON, Canada

identify at-risk individuals; however, a genome wide association study (GWAS) iden-
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(rs2647087) and thiopurine-induced pancreatitis.

London Health Sciences Centre, London,
ON, Canada

tified a strong association between the Class II HLA gene region polymorphism
Aim: To independently confirm the findings of the GWAS in an IBD cohort, to eval-
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uate its utility in clinical practice and to offer a novel AZA treatment algorithm for
IBD based on pharmacogenomic principles.
Methods: A retrospective cohort study evaluated 373 AZA-exposed IBD patients
from a tertiary care academic centre in London, Canada. Due to the limited number
of patients taking mercaptopurine (MP), such patients were not included this cohort.
All subjects underwent screening for the single nucleotide polymorphism (SNP)
rs2647087 mapped to the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype and
were sub-divided based on the presence (n = 13) or absence (n = 360) of an AZAinduced pancreatitis diagnosis. The risk of AZA-induced pancreatitis was assessed
based on rs2647087 genotype.
Results: The risk of pancreatitis during AZA-therapy was highly predictable and
genotype dependent: 0.53% for wild type (A/A), 4.25% (OR = 4.19, 95% CI 1.0236.45, P = 0.044) for heterozygous (A/C), and 14.63% (OR = 15.83, 95% CI 3.80145.26, P = 0.0001) for homozygous variant (C/C) patients.
Conclusions: The class II HLA region (at rs2647087) is an important marker of
AZA-induced pancreatitis risk. We propose a simple and clinically implementable
algorithm based on rs2647087 and TPMT genotypes for AZA selection and dosing
for patients with IBD.

The Handling Editor for this article was Professor Ailsa Hart, and it was accepted for publication after full peer-review.

Aliment Pharmacol Ther. 2018;47:615–620.

wileyonlinelibrary.com/journal/apt

© 2017 John Wiley & Sons Ltd

|

615

616

|

WILSON

1 | INTRODUCTION

ET AL.

AZA-induced pancreatitis were required to meet two of the following three criteria: a minimum elevation in serum lipase three times

Immunosuppressive therapy is integral to the management of inflam-

the upper limit of normal, clinical symptoms of nausea, vomiting and

matory bowel disease (IBD) including Crohn’s disease (CD) and ulcer-

characteristic abdominal pain or radiological evidence of acute pan-

ative colitis (UC). Azathioprine (AZA) is one of several treatments

creatitis.9 The diagnosis of pancreatitis was made by an independent

1,2

clinician less than 3 months after exposure to azathioprine in the

Due to high costs associated with biologics, payers sometimes

absence of other causative factors (alcohol, gallstones, other drugs

require patients to be resistant or intolerant to AZA prior to the

causing pancreatitis, etc.). Severity of acute pancreatitis was classi-

approval of such agents. Currently, several international societies

fied based on the revised Atlanta criteria.9 The study protocol was

and federal agencies discourage AZA use as a monotherapy for IBD;

approved by the Western University Health Sciences Research

however, its use as combination therapy with anti-TNF agents

Ethics Board. Data collected on all subjects included IBD diagnosis

used to manage the dysregulated inflammatory response of IBD.

2-5

remains a gold standard in high risk IBD patients.

(CD, UC), age, sex, height, weight, smoking history, disease activity,

AZA is associated with a few, but significant, toxicities that can

and AZA response. Additional data specific to AZA-induced pancre-

limit its use in clinical practice. These include nausea, vomiting,

atitis cases were collected including dose and duration of AZA expo-

myelosuppression, hepatotoxcity or acute pancreatitis.6 AZA-induced

sure preceding the onset of acute pancreatitis, hospitalisation and

pancreatitis is an idiosyncratic drug reaction that affects 2%-7% of

duration, acute pancreatitis severity, biochemical parameters of pan-

AZA-treated patients with IBD.6,7 Risk factors associated with its

creatitis, results of abdominal imaging, and concomitant medications.

onset include cigarette smoking and glucocorticoid exposure; how-

Subjects were followed up for a minimum of 6 months up to

ever, there are no predictive tests used clinically to identify patients

4 years.

at risk for AZA-induced pancreatitis.7
Recently, an association between the human leucocyte antigen
(HLA) gene region and AZA-induced pancreatitis has been identi-

2.2 | Genotypic analysis

fied.8 The genome wide association study (GWAS) recognised an

DNA was extracted from whole blood using a standard DNA extrac-

association between AZA-induced pancreatitis and the single nucleo-

tion protocol (QIAmp DNA Mini Kit, Qiagen, Valencia, California) or

tide polymorphism (SNP) rs2647087 that maps to the HLA-

using the MagNA Pure Compact instrument (Roche, Laval, Quebec,

DQA1*02:01-HLA-DRB1*07:01 haplotype (odds ratio, OR, 2.59).

Canada).

Heterozygous (A/C) and homozygous (C/C) carriers of the variant

C_16052296_10) (Applied Biosystems, Carlsbad, CA) was used to

allele had 2.5- and 5-fold higher risk of developing AZA-induced

determine the presence of wild-type and/or variant alleles in the

pancreatitis respectively compared to those who are homozygous

class II HLA gene region at rs2647087 mapped to the HLA-

for the common allele (A/A).8

DQA1*02:01-HLA-DRB1*07-01 haplotype in AZA-exposed IBD sub-

TaqMan

allelic

discrimination

assay

(assay

id:

Given the clinical relevance and potential impact of the findings

jects (n = 373). Each genotyping experiment included three positive

with regard to the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype,

controls and one negative control. Five per cent of samples were

the aim of our study was to validate the findings in a large and inde-

genotyped in duplicate. All duplicated genotypes were congruent.

pendent cohort of patients with IBD and to further delineate an IBD
AZA treatment algorithm based on pharmacogenomic principles.

2 | MATERIALS AND METHODS
2.1 | Subjects
A retrospective cohort study was carried out in 373 individuals with

2.3 | Statistical analysis
Statistical analyses were performed using

R

statistical software with

the “epitools” (Epidemiology Tools) package.10,11 Genotype frequencies were compared using a 2 9 3 contingency table with a correction for small sample size and Fisher’s exact test; allele frequencies
were compared using a 2 9 2 contingency table and Fisher’s exact

IBD exposed to AZA. Patients taking mercaptopurine (MP) were not

test. Two-sided P-values, odds ratios (OR) and 95% confidence (CI)

included in the final cohort. Subject recruitment took place between

were calculated. P-values <.05 were deemed to be statistically signif-

July 2012 and March 2017. This cohort was assembled from IBD

icant.

patients (n = 591) being considered for AZA therapy who were
referred to the London Health Sciences Centre Personalized Medicine Service (London, Canada) for thiopurine S-methyltransferase

3 | RESULTS

(TPMT) genotyping. Eligible subjects were 18 years of age or older
and had a histopathological diagnosis of CD or UC. All subjects were

Figure 1 highlights patient selection based on the STROBE state-

required to have been prescribed AZA by their treating clinician and

ment.12 Three hundred and seventy-three subjects with IBD were

for their exposure to be documented in their patient chart. Control

exposed to AZA and included in this study (245 CD and 128 UC).

subjects (no history of AZA-induced pancreatitis) were required to

Thirteen subjects were diagnosed with AZA-induced pancreatitis.

be on AZA for a minimum of 6 months. Subjects diagnosed with

Baseline characteristics and demographics are described in Table 1.
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IBD patients enrolled and
screened:
n = 591
No exposure to AZA:
n = 218
AZA-exposed IBD
subjects:
n = 373

Diagnosis of acute
pancreatitis
n = 14

No evidence of acute
pancreatitis
n = 360

Available for HLA
genotyping
n = 13

Available for HLA
genotyping
n = 360

Not AZA-induced
pancreatitis
n=1
F I G U R E 1 Patient selection pathway.
Inflammatory bowel disease, IBD;
azathioprine, AZA; months, mo
T A B L E 1 Subject demographics

T A B L E 2 Acute AZA-induced pancreatitis in an IBD cohort

Control

AZA-induced
pancreatitis

Subject

AZA
dose (mg)

Time
to AP (d)

Severity
of APa

Smoker

Steroid
exposure

N

360

13

1

50

22

Mild

Y

Y

CD (%)

234 (65)

11 (84.6)

2

125

26

Mild

Y

Y

76 (21.1)

3 (23.1)

3

200

9

Mild

N

N

110 (30.6)

8 (61.5)

4

300

14

Mild

N

Y

Ileitis (%)
Ileo-colitis (%)
Colitis (%)
UC (%)

48 (13.3)
126 (35)

0 (0)

5

200

26

Mild

N

Y

2 (15.4)

6

100

16

Mild

Y

Y

Pancolitis (%)

80 (22.2)

1 (7.7)

7

50

14

Mild

N

N

Left-sided colitis (%)

40 (11.1)

1 (7.7)

8

50

28

Mild

Y

N

0 (0)

9

50

28

Mild

N

N

7 (53.8)

10

50

30

Mild

N

N

Proctitis (%)

6 (1.7)

Female (%)

196 (54.4)

Age (mean  SD; y)

41.25  15.98

46.15  11.87

11

200

25

Mild

N

N

BMI (mean  SD; kg/m2)

26.19  5.99

27.51  7.31

12

250

27

Mild

N

N

13

50

20

Mild

Y

N

Smoking history (%)

148 (41.1)

5 (38.5)

Disease duration
(mean  SD; mo)

104.79  115.17

95.75  109.18

AZA, Azathioprine; CD, Crohn’s disease; UC, ulcerative colitis; BMI, body
mass index; SD, standard deviation.

AP, Acute pancreatitis; AZA, azathioprine; IBD, inflammatory bowel disease.
a
Based on the revised Atlanta Criteria (2013).

classified by the presence or absence of acute pancreatitis are disTable 2 provides further description on the individuals diagnosed

played in Table 3. Across the entire cohort, the HLA rs2647087

with AZA-induced pancreatitis. The mean time to the onset of acute

genotype was in Hardy-Weinberg equilibrium. There was a strong

pancreatitis from the time of first exposure to AZA was

association between carriers of the variant C allele and AZA-induced

21.9  6.7 days. Subjects were exposed to AZA doses ranging from

pancreatitis (OR = 5.63, 95% CI 2.41-13.15, P<0.0001) (Figure 2).

50 mg to 300 mg, with a mean dose of 128.85  90.05 mg. All

The absolute risk of AZA-induced pancreatitis in the total population

cases of acute pancreatitis were mild based on the revised Atlanta

was 3.49%, with a median time to pancreatitis of 25 days. However,

criteria.9 with no associated complications. All subjects required

when stratified by rs2647087 genotype, wild-type carriers (A/A) had

admission to hospital. The mean length of stay was 2  1.63 days.

an absolute risk of 0.53%, while heterozygous (A/C) and homozy-

All subjects underwent genotyping for the class II HLA gene

gous (C/C) variant carriers had absolute risks of AZA-induced pan-

region at rs2647087. The genotype and minor allele frequencies

creatitis of 4.25% (n = 6/135; OR = 4.19, 95% CI 1.02-36.45,

|

618

WILSON

T A B L E 3 Genotype and allele frequencies for HLA-DQA1-HLADRB1 rs2647087
HLA-DQA1-HLA-DRB1
rs2647087

ET AL.

rs2647087 SNP appear to have a much lower than average risk for
pancreatitis (0.54%). The study by Heap et al noted a 2.5- and fivefold higher risk of pancreatitis for those who are rs2647087 A/C or

No pancreatitis
(n = 360)

Pancreatitis
(n = 13)

A/A

189 (52.5)

1 (7.7)

C and C/C patients respectively. Although patients on MP were not

A/C

135 (37.5)

6 (46.15)

directly assessed in this study, azathioprine is a prodrug of MP. In

C/C

35 (9.7)

6 (46.15)

the study by Heap et al patients on either azathioprine or MP had

Genotype, n (%)

C/C compared to those who are A/A.8 Our finding suggests the pancreatitis risk is in fact much higher, 4- and 15-fold for rs2647087 A/

been enrolled and there was no indication that being on either medi-

Allele frequency
A

0.7125

0.3100

C

0.2847

0.6923

cation alters the risk for pancreatitis.8
Heap et al8 questioned whether or not this association suggests
AZA-associated pancreatitis is a T-cell mediated response given the
role of class II HLA molecules in T-lymphocyte activation. However,

200

A/C

A/A

C/C

n = 13

n = 360

% of patients

150

common genetic polymorphisms identified via GWAS cannot be
assumed to causally explain disease phenotypes. These polymorphisms are often only “surrogates of ‘unknown’ causal factors [inherited in linkage disequilibrium].”13 It cannot be inferred that a
polymorphism in the class II HLA gene region plays a functional role
in the onset of AZA-induced pancreatitis. Further mechanistic stud-

100

ies are needed to determine if polymorphisms within the class II
HLA gene region play a functional role in the onset of AZA-induced

50

pancreatitis.
Interestingly, this is not the first study to link polymorphisms in
HLA molecules to adverse drug reactions. Variant genotypes in

N

o

pa

Pa
n

nc

cr

re

ea

at

tit

iti

is

s

0

F I G U R E 2 Genotype frequency stratified by pancreatitis
diagnosis. Genotypes are expressed as a percentage of the total
population of the pancreatitis cases (n = 13) and controls (n = 360).
Number, n

class II molecules occur more frequently in b-lactam-associated hepatotoxicity.14,15 In addition, in a landmark trial by Mallal et al16 carriers of the HLA-B*5701 allele had a marked increased risk for an
abacavir-related hypersensitivity reaction, leading to significant
patient morbidity and immediate withdrawal of an otherwise welltolerated and effective treatment for the human immunodeficiency
virus (HIV). It was concluded that prospective screening for this
genotype among HIV patients eligible for abacavir was warranted
for patient safety and cost-effectiveness. Currently, both profes-

P = 0.044) and 14.63% (n = 6/35; OR = 15.83, 95% CI 3.80-145.26,

sional society guidelines and the US Food and Drug Administration

P = 0.0001) respectively. Of note, A/C and C/C genotypes were not

(FDA) recommend that patients be screened for the HLA-B*5701

associated with AZA-induced nausea and/or vomiting and/or abdom-

allele as a companion diagnostic test before being initiated on ther-

inal pain in the absence of lipase elevation or clinically diagnosed

apy.17 Although caution must be taken when interpreting these

pancreatitis.

results given the small number of cases, this study highlights the
potential utility of prospectively screening IBD patients being considered for AZA therapy for the rs2647087genotype given its pre-

4 | DISCUSSION

dictive effect and the fact that other, potentially more efficacious,
treatments are available for patients deemed to be higher risk for

The use of AZA for the treatment of CD and UC has been

AZA-induced pancreatitis.

well-documented over the last 4 decades. Drug-induced acute

Accordingly, we propose a genotype-guided algorithm for the

pancreatitis is an unfortunate, unpredictable and dose-independent

treatment of patients with IBD with AZA, which takes into account

complication that can arise with AZA exposure. The prevalence of

TPMT genotype as well as the class II HLA rs2647087 genotype

AZA-induced acute pancreatitis in our IBD population (3.49%) aligns

(Figure 3). This would allow rs2647087 homozygous and even

with the 2%-7% rate reported in the literature.6,7 Pancreatitis

heterozygous variant carriers to be excluded from AZA therapy, min-

appears to be mild in these individuals, without evidence of organ

imising the risk of adverse drug effects and a more timely and sys-

failure or lasting complication.

tematic progression to other more effective IBD therapies. Patients

Our findings confirm an important role of the class II HLA gene

who are homozygous for the rs2647087 wild-type allele (A/A) would

region at rs2647087 as demonstrated in the GWAS by Heap et al.8

be candidates for a trial of azathioprine, where the risk of myelosup-

However, we note that those who are wild-type (A/A) for the

pression is mitigated through TPMT genotype testing.

WILSON
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Inflammatory bowel disease requiring azathioprine treatment

HLA-DQA1-HLA-DRB1 rs2647087 genotype testing

A/A genotype

A/C genotype

C/C genotype

Pancreatitis risk

Pancreatitis risk ≅

Pancreatitis risk ≅

<1 %

4%

15 %

Consideration of
azathioprine initiation

Select alternative
treatment if possible.
If no alternative
feasible, proceed with
close monitoring of
clinical symptoms.
Adjust dose based on
TPMT genotype

Proceed with
azathioprine.

Adjust dose based
on TPMT genotype

STOP: Select
alternative
treatment

TPMT genotype testing for prevention of myelotoxicity
FDA recommendation: azathioprine product information
Toronto Consensus: UC treatment guidelines

Therapeutic dose

recommendation

Wild type

Heterozygous

Homozygous

genotype:

variant genotype:

variant genotype:

Extensive

Intermediate

Poormetabolizer

metabolizer

metabolizer

Proceed with

Proceed with 50%

Select alternate

standard dosing

dose reduction

therapy

F I G U R E 3 Proposed azathioprine treatment algorithm based on HLA rs2647087 and TPMT genotypes. Thiopurine S-methyltransferase,
TPMT; Food and Drug Administration, FDA; human leucocyte antigen, HLA

Currently, payers across many jurisdictions require that patients

companion diagnostic approach for patients who are to be pre-

try and fail low cost immunomodulators, such as AZA, prior to the

scribed AZA, similar to what is already the case for medications such

18

It should

as abacavir. We recommend that HLA-DQA1-HLA-DRB (rs2647087)

be noted that treatment of AZA-induced pancreatitis results in

and TPMT genotyping are carried out prior to initiation of AZA

added health care costs. Hospitalisation costs alone relating to acute

where the rs2647087 wild-type (A/A) patients are then prescribed a

pancreatitis can be over $10,000 (US) per individual, depending on

TPMT genotype-guided AZA dose. Dedicated cost-benefit analyses

initiation of more effective and costly biological therapies.

19,20

the length of stay and investigations pursued.

In summary, class II HLA gene region at rs2647087 appears to

would be useful to further elucidate the utility of our proposed
approach in clinical practice.

be an important marker of AZA-induced pancreatitis risk, though
caution must be taken due to the small number pancreatitis cases
identified in this study. The marked increase in risk for pancreatitis
among carriers of the variant allele provides a strong rationale for a

ACKNOWLEGDEMENTS
Declaration of personal interests: None.

|

620

WILSON

Declaration of funding interests: This work was supported by the
Wolfe Medical Research Chair in Pharmacogenomics (RBK) and the
Canadian Institutes of Health Research (MOP-89753 to RBK,
201411IBD-339942-229066 to AW) as well as the Drug Safety and
Effectiveness Network (DSEN-PREVENT, FRN-117588 to RBK),
Cancer Care Ontario (CCO Research Chair Award (Tier-1) in Experimental Therapeutics to RBK), the Canadian Association of Gastroenterology and Crohn’s Colitis Canada (201411IBD-339942-229066 to
AW).

AUTHORSHIP
Guarantor of the article: Dr. Richard B. Kim.
Author contributions: RBK supervised the study. AW, JCG, TP,
NC, RK, BY, VJ, NK, MS, MB, and KM were involved in data acquisition. AW, WAT and RBK contributed to the study concept and
design. LEJ and AW carried out all data analyses. RBK, AW and
WAT were involved in data interpretation. Statistical analyses were
performed by RR and AW. AW drafted the manuscript. Critical revisions were carried out by RBK, WAT, JCG, TP, NC, RK, BY, VJ, NK,
MS, MB, and KM. All authors had full access to all the data. All
authors reviewed and approved the final version of this manuscript.
No writing service was used for this manuscript.

ORCID
R. B. Kim

http://orcid.org/0000-0001-8148-1632

LINKED CONTENT
This article is linked to Teich et al and Wilson et al papers. To view
these articles visit https://doi.org/10.1111/apt.14545 and https://
doi.org/10.1111/apt.14562.

REFERENCES
1. Chebli LA, Chaves LDdM, Pimentel FF, et al. Azathioprine maintains
long-term steroid-free remission through 3 years in patients with
steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16:613619.
2. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association institute guideline on the use of thiopurines,
methotrexate, and anti–TNF-a biologic drugs for the induction and
maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459-1463.
3. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis:
the toronto consensus. Gastroenterology. 2015;148:1035-1058.e3.
4. Panccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or
infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology. 2011;140:S-134.

ET AL.

5. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med.
2010;362:1383-1395.
6. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in
the management of inflammatory bowel disease: short- and longterm toxicity. Ann Intern Med. 1989;111:641-649.
7. Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced acute
pancreatitis in patients with inflammatory bowel diseases—a
prospective study on incidence and severity. Journal of Crohn’s and
Colitis. 2015;10:61-68.
8. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1
variants confer susceptibility to pancreatitis induced by thiopurine
immunosuppressants. Nat Genet. 2014;46:1131-1134.
9. Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400.
10. R Core Team. R: a Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
11. Aragon TJ, Fay MP, Wollschlaeger D, Omidpanah A. Tools for Training and Practicing Epidemiologists Including Methods for two-way and
Multi-way Contingency Tables. 2017. edition 0.5-9.
12. Von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The
strengthening the reporting of observational studies in epidemiology
(STROBE)statement: guidelines for reporting observational studies. J
Clin Epidemiol. 2008;61:344-349.
13. Chakravarti A, Turner TN. Revealing rate-limiting steps in complex
disease biology: the crucial importance of studying rare, extremephenotype families. BioEssays. 2016;38:578-586.
14. O’donohue J, Oien K, Donaldson P, et al. Co-amoxiclav jaundice:
clinical and histological features and HLA class II association. Gut.
2000;47:717-720.
15. Hautekeete ML, Horsmans Y, van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate–induced hepatitis. Gastroenterology.
1999;117:1181-1186.
16. Mallal S, Phillips E, Carosi G, et al. HLA-B* 5701 screening for
hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
17. Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir
hypersensitivity. PLoS Currents. 2010;2:RRN1203.
18. Cutler M, Glasgow K. IBD Impact Report, 2012.
19. Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States.
Pancreas. 2007;35:302-307.
20. Teshima CW, Bridges RJ, Fedorak RN. Canadian digestive health
foundation public impact series 5: pancreatitis in Canada. Incidence,
prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2012;26:544-545.

How to cite this article: Wilson A, Jansen LE, Rose RV, et al.
HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of
azathioprine-induced pancreatitis in patients with
inflammatory bowel disease. Aliment Pharmacol Ther.
2018;47:615–620. https://doi.org/10.1111/apt.14483

